Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study
Sponsor: Fatima Tariq
Summary
In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound. The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.
Key Details
Gender
FEMALE
Age Range
16 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-05-01
Completion Date
2026-07-31
Last Updated
2026-03-10
Healthy Volunteers
No
Conditions
Interventions
Myoinositol
In group A, females will be prescribed oral myoinositol 1g twice daily for 3 months.
Metformin
In group B, females will be prescribed oral sustained-release metformin 850 mg twice daily for 3 months.
Locations (1)
CMH Gujranwala
Gujranwala, Punjab Province, Pakistan